Figures
- FIGURE 1
The Convergence of Opinion on Suggestions and Evidence process. PICO: Patient, Intervention, Comparator, Outcomes.
Tables
- TABLE 1
Task Force suggestions and interpretations
Task Force Interpretation Suggests The Task Force believes that the benefits exceed the harms and the intervention should be used Makes no suggestion for or against The Task Force believes that the benefit–risk ratio is uncertain, more evidence is needed and, for now, clinical equipoise exists Suggests against/not The Task Force believes that the harms may exceed the benefits and, therefore, the intervention should not be used except in the context of a clinical trial - TABLE 2
Summary of Task Force suggestions#
The Task Force made the following consensus suggestions For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not mechanically ventilated, the Task Force suggests remdesivir: 86% suggest remdesivir, 11% make no suggestion for or against remdesivir, and 3% suggest not using remdesivir For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force suggests remdesivir: 77% suggest remdesivir, 16% make no suggestion for or against remdesivir, and 7% suggest not using remdesivir For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not mechanically ventilated, the Task Force suggests dexamethasone: 84% suggest dexamethasone, 13% make no suggestion for or against dexamethasone, and 3% suggest not using dexamethasone For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force suggests dexamethasone: 96% suggest dexamethasone, 1% make no suggestion for or against dexamethasone, and 3% suggest not using dexamethasone For adults who were hospitalised with COVID-19 pneumonia and had confirmed venous thromboembolism, the Task Force suggests therapeutic anticoagulant therapy for 3 months to reduce the risk of recurrent venous thromboembolism: 95% favour therapeutic anticoagulant therapy for 3 months, 1% favour therapeutic anticoagulant therapy for >3 months, and 4% make no suggestion for either approach For hospitalised patients with COVID-19 pneumonia who require supplemental oxygen but are not mechanically ventilated, the Task Force suggests not using HCQ except within a clinical trial: 3% suggest HCQ, 9% make no suggestion for or against HCQ, and 88% suggest not using HCQ For hospitalised patients with COVID-19 pneumonia who are mechanically ventilated, the Task Force suggests not using HCQ except within a clinical trial: 0% suggest HCQ, 9% make no suggestion for or against HCQ, and 91% suggest not using HCQ COVID-19: coronavirus disease 2019; HCQ: hydroxychloroquine. #: >70% agreement among Task Force members.
- TABLE 3
Summary of research priorities
The Task Force identified the following research needs for previously hospitalised patients with COVID-19 pneumonia who were discharged in the past 30–60 days Routine testing to establish a new baseline? Pulmonary function testing 6-min walk test Computed tomography of the chest Transthoracic echocardiography Cardiopulmonary exercise testing Continue prophylactic anticoagulant therapy as outpatients until the D-dimer normalises? Serological testing to assess immune response to the infection? Attending medical visits without screening for active infection if serological tests positive? Serological testing of household contacts to determine if mild or asymptomatic infection? Referral to a multidisciplinary clinic for post-intensive care syndrome? Referral to pulmonary rehabilitation regardless of lung function? Routine screening for: Cognitive impairment Depression Anxiety Post-traumatic stress disorder Routine referral for mental health counselling? COVID-19: coronavirus disease 2019.
Supplementary Material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary_material ERR-0287-2020_Supplementary_material
Vol 29 Issue 157
Table of Contents
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)
